A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Hypertriglyceridemia

In brief

The primary objective of the study is to determine the effect of MAR001 as compared to placebo on levels of the triglycerides (TG) in the postprandial state in adults with elevated TG.

Key facts

Study ID

NCT07199309

Run by

Marea Therapeutics

People needed

30

Starts

2025-09-26

Expected to finish

2026-11-01

Last updated by the study team

2025-11-06

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Willingness to provide informed consent and comply with the intervention and all study assessments
• Two fasting TG collected at two separate, consecutive visits at least 7 days apart during the Screening period
• HbA1c ≥ 5.7% and ≤ 8.5%
• Stable diet for a minimum of 3 months prior to screening and with no plans to change diet through duration of study
• Stable drug regimen (appropriate if relevant) prior to screening visit and no planned changes during screening or trial participation

You may not qualify if…

• Acute or chronic liver disease
• Diabetes medications (other than metformin)
• History of type 1 diabetes mellitus or history of diabetic ketoacidosis
• Newly diagnosed T2DM
• Participants with known active hepatitis A, B, or C
• Participants who are known to have uncontrolled human immunodeficiency virus (HIV) infection
• Uncontrolled hypothyroidism
• Any condition that prevents the participant from complying with study procedures

Where it is running

• Marea Site 301 — Chula Vista, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.